Skip to main content

Table 2 Comparison between groups A and B according to clinical outcome and overall survival

From: Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival—prospective interventional study

 

Group A

Group B

p value

Average VAS score at the first week

 Mean ± standard deviation

3.9 ± 1

6.6 ± 0.7

< 0.001

 Median (minimum–maximum)

4 (3–6)

7 (6–8)

Fever days, n (%)

< 5 days

8 (38.1%)

2 (11.1%)

0.004

5–10 days

12 (57.1%)

7 (38.9%)

 > 10 days

1 (4.8%)

9 (50%)

Fever days, median (interquartile range)

5 (2)

10 (5)

0.003

Free-time-to-PES symptoms (days)

 Mean ± standard deviation

7.2 ± 3.6

14.5 ± 4.5

< 0.001

 Median (minimum–maximum)

6 (3–17)

14 (5–21)

Ascites occurrence, number of patients (%)

2 (13.3%)

3 (23.1%)

0.5

Frequency of ALT levels elevation

 At month 1

9 (60%)

12 (92.3%)

0.084 (FE)

 At month 3

7 (46.7%)

8 (61.5%)

0.431

Frequency of AST levels elevation

 At month 1

11 (73.3%)

8 (61.5%)

0.689 (FE)

 At month 3

11 (73.3%)

10 (76.9%)

1.000 (FE)

Frequency of total bilirubin levels elevation

 At month 1

5 (33.3%)

4 (30.8%)

1.000 (FE)

 At month 3

7 (46.7%)

6 (46.2%)

0.978

Frequency of INR levels elevation

 At month 1

2 (13.3%)

2 (15.4%)

1.000 (FE)

 At month 3

3 (20%)

2 (15.4%)

1.000 (FE)

  1. ALT Alanine aminotransferase, AST Aspartate aminotransferase, FE Fisher exact, INR International normalised ratio, PES Post-embolisation syndrome, VAS Visual analogue scale